• In the News

    November 21, 2016
    Intarcia Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of ITCA 650 in Type 2 Diabetes

    Read more

  • Message from the CEO

    Our NDA for ITCA 650 in Type 2 Diabetes Has Been Submitted to the FDA Seeking U.S. Marketing Approval: Winning for Patients Now a Significant Step Closer

    NDA Submission Milestone also triggers third $100M payment to Intarcia from our 2015 Royalty financing. This adds to the $215M first close equity financing that closed mid-September. A second close of the financing is planned before the end of the 2016. We look forward to working with the FDA during the review and moving with a sense of urgency to prepare the organization to bring our first medicine to patients.

    Read more

  • Chairman & CEO Kurt Graves Explains the Vision and Culture of Intarcia

    What immediately sets Intarcia apart from other companies is what’s most visible – our product candidate that is built on amazing technology and chemistry. But what most outsiders cannot see is even more amazing – our people and our culture. Our people have a will to win. They are not intimidated by the skeptics who doubt that a relatively small biotech can change the course of treatment in serious disease. They say, "Watch us!"

    Hear Kurt Graves speak on this topic ›